{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:52:50Z","timestamp":1777319570360,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vhri.2025.101553","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T17:37:20Z","timestamp":1765561040000},"page":"101553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Custo-Efetividade da Teriparatida em Homens com Osteoporose Grave no Brasil"],"prefix":"10.1016","volume":"53","author":[{"given":"Cid Manso de Mello","family":"Vianna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Bittencourt Gonzalez","family":"Mosegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00e1cio de Mendon\u00e7a","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayna Felic\u00edssimo Gomes de Souza","family":"Bandeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Paulo da Silva","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vhri.2025.101553_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1590\/S1413-78522001000200007","article-title":"Osteoporose","volume":"9","author":"Gali","year":"2001","journal-title":"Acta Ortop Bras"},{"issue":"1","key":"10.1016\/j.vhri.2025.101553_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"4","key":"10.1016\/j.vhri.2025.101553_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1210\/er.2008-0002","article-title":"Osteoporosis in men","volume":"29","author":"Khosla","year":"2008","journal-title":"Endocr Rev"},{"issue":"suppl 3","key":"10.1016\/j.vhri.2025.101553_bib4","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1098-3597(06)80020-7","article-title":"Osteoporosis in men: prevalence and investigation","volume":"8","author":"Cauley","year":"2006","journal-title":"Clin Cornerstone"},{"issue":"1","key":"10.1016\/j.vhri.2025.101553_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s001980050197","article-title":"Survival after hip fracture: short- and long-term excess mortality according to age and gender","volume":"10","author":"Fors\u00e9n","year":"1999","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.vhri.2025.101553_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ageing\/afp221","article-title":"Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival","volume":"39","author":"Kannegaard","year":"2010","journal-title":"Age Ageing"},{"issue":"3","key":"10.1016\/j.vhri.2025.101553_bib7","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1590\/1809-4503201400030012","article-title":"Expenditures on the treatment of osteoporosis in the elderly in Brazil (2008-2010): analysis of associated factors","volume":"17","author":"Moraes","year":"2014","journal-title":"Rev Bras Epidemiol"},{"issue":"2","key":"10.1016\/j.vhri.2025.101553_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1590\/S0034-89102009000900014","article-title":"Preval\u00eancia de diagn\u00f3stico auto-referido de osteoporose, Brasil, 2006","volume":"43","author":"Martini","year":"2009","journal-title":"Rev Sa\u00fade Publ"},{"key":"10.1016\/j.vhri.2025.101553_bib10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.rbr.2017.06.001","article-title":"Diretrizes brasileiras para o diagn\u00f3stico e tratamento da osteoporose em mulheres na p\u00f3s-menopausa","volume":"57","author":"Radominski","year":"2017","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"10.1016\/j.vhri.2025.101553_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.vhri.2025.101553_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","article-title":"Evidence-Based Guideline for the management of osteoporosis in men","volume":"20","author":"Fuggle","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.vhri.2025.101553_bib13","article-title":"Therapy of osteoporosis in men with teriparatide","volume":"2011","author":"Cusano","year":"2011","journal-title":"J Osteoporos"},{"issue":"4","key":"10.1016\/j.vhri.2025.101553_bib16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40273-022-01239-2","article-title":"Cost effectiveness analyses of interventions for osteoporosis in men: a systematic literature review","volume":"41","author":"Li","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vhri.2025.101553_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"9319","key":"10.1016\/j.vhri.2025.101553_bib18","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","article-title":"Epidemiology and outcomes of osteoporotic fractures","volume":"359","author":"Cummings","year":"2002","journal-title":"Lancet"},{"issue":"2A","key":"10.1016\/j.vhri.2025.101553_bib19","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1016\/S0002-9343(97)90023-1","article-title":"The socioeconomic burden of fractures: today and in the 21st century","volume":"103","author":"Johnell","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.vhri.2025.101553_bib22","series-title":"Denosumabe e Teriparatida Para o Tratamento Indiv\u00edduos Com Osteoporose Grave e Falha Terap\u00eautica Aos Medicamentos Dispon\u00edveis No Sistema \u00danico de Sa\u00fade. Secretaria de Ci\u00eancia Tecnologia Inova\u00e7\u00e3o e Insumos Estrat\u00e9gicos em Sa\u00fade","year":"2022"},{"issue":"29","key":"10.1016\/j.vhri.2025.101553_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6290","article-title":"Treatment of established osteoporosis: a systematic review and cost-utility analysis","volume":"6","author":"Kanis","year":"2002","journal-title":"Health Technol Assess"},{"issue":"29","key":"10.1016\/j.vhri.2025.101553_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24290","article-title":"Denosumab, raloxifene, Romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation","volume":"24","author":"Davis","year":"2020","journal-title":"Health Technol Assess"},{"issue":"5","key":"10.1016\/j.vhri.2025.101553_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1524-4733.2007.00188.x","article-title":"The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks","volume":"10","author":"Van Staa","year":"2007","journal-title":"Value Health"},{"issue":"78","key":"10.1016\/j.vhri.2025.101553_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20780","article-title":"A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures","volume":"20","author":"Davis","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vhri.2025.101553_bib27","author":"Kanis"},{"key":"10.1016\/j.vhri.2025.101553_bib28","series-title":"Diretriz de Avalia\u00e7\u00e3o Econ\u00f4mica. Brasil. Minist\u00e9rio Da Sa\u00fade. Secretaria de Ci\u00eancia. Tecnologica e Insumos Estrat\u00e9gicos","author":"Metodol\u00f3gicas","year":"2014"},{"key":"10.1016\/j.vhri.2025.101553_bib37","author":"Farmoqu\u00edmica"},{"issue":"3","key":"10.1016\/j.vhri.2025.101553_bib41","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","article-title":"Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS","volume":"29","author":"Svedbom","year":"2018","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.vhri.2025.101553_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00223-008-9117-6","article-title":"Utility values associated with osteoporotic fracture: a systematic review of the literature","volume":"82","author":"Hiligsmann","year":"2008","journal-title":"Calcif Tissue Int"},{"issue":"10117","key":"10.1016\/j.vhri.2025.101553_bib46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vhri.2025.101553_bib47","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"8","key":"10.1016\/j.vhri.2025.101553_bib48","doi-asserted-by":"crossref","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med Sci Monit"},{"issue":"3","key":"10.1016\/j.vhri.2025.101553_bib49","first-page":"200","article-title":"Safety and effectiveness of teriparatide vs alendronate in postmenopausal osteoporosis: a prospective non randomized clinical study","volume":"13","author":"Caggiari","year":"2016","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.vhri.2025.101553_bib30","author":"Package"},{"issue":"4","key":"10.1016\/j.vhri.2025.101553_bib32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40273-022-01239-2","article-title":"Cost effectiveness analyses of interventions for osteoporosis in men: a systematic literature review","volume":"41","author":"Li","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2025.101553_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bone.2013.11.002","article-title":"Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective","volume":"59","author":"Parthan","year":"2014","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.vhri.2025.101553_bib34","article-title":"Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective","volume":"2015","author":"Silverman","year":"2015","journal-title":"J Osteoporos"},{"issue":"22","key":"10.1016\/j.vhri.2025.101553_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.vhri.2025.101553_bib43","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12955-022-01959-1","article-title":"Combined quality of life and survival for estimation of long-term health outcome of patients with stroke","volume":"20","author":"Butsing","year":"2022","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.vhri.2025.101553_bib44","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/01.STR.32.4.964","article-title":"Health-related quality of life after stroke A comprehensive review","volume":"32","author":"Tengs","year":"2001","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.vhri.2025.101553_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12955-020-01407-y","article-title":"Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review","volume":"18","author":"Betts","year":"2020","journal-title":"Health Qual Life Outcomes"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925004790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:24:35Z","timestamp":1777317875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925004790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"alternative-id":["S2212109925004790"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101553","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Custo-Efetividade da Teriparatida em Homens com Osteoporose Grave no Brasil","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101553"}}